{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:25:41Z","timestamp":1762917941881,"version":"3.44.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annalsthoracicsurgery.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Annals of Thoracic Surgery"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.athoracsur.2018.08.037","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T05:37:46Z","timestamp":1539063466000},"page":"418-424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Clinicopathologic Features of Thymoma With the Expression of Programmed Death\u00a0Ligand 1"],"prefix":"10.1016","volume":"107","author":[{"given":"Shuhei","family":"Hakiri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Ozeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taketo","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Yatabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.athoracsur.2018.08.037_bib1","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.athoracsur.2003.07.042","article-title":"WHO histologic classification is a prognostic indicator in thymoma","volume":"77","author":"Kondo","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.athoracsur.2018.08.037_bib2","unstructured":"David SE, Douglas EW, Dara LA, et al. NCCN Guidelines Version 2, 2018. Thymomas and Thymic Carcinomas. Available at https:\/\/www.nccn.org\/. Accessed February 20, 2018."},{"key":"10.1016\/j.athoracsur.2018.08.037_bib3","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/jjco\/hyx138","article-title":"JLCS medical practice guidelines for thymic tumors: summary of recommendations","volume":"47","author":"Yokoi","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.athoracsur.2018.08.037_bib4","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1 positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2018.08.037_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2018.08.037_bib6","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2018.08.037_bib7","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1 positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.athoracsur.2018.08.037_bib8","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2018.08.037_bib9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.athoracsur.2018.08.037_bib10","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/modpathol.2016.117","article-title":"Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas","volume":"29","author":"Scheel","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.athoracsur.2018.08.037_bib11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.lungcan.2016.05.007","article-title":"Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: impact on treatment efficacy and alteration in expression after chemotherapy","volume":"99","author":"Katsuya","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.athoracsur.2018.08.037_bib12","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.athoracsur.2018.08.037_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lungcan.2016.12.005","article-title":"Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs)","volume":"104","author":"Tiseo","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.athoracsur.2018.08.037_bib14","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/modpathol.2017.6","article-title":"Expression of PD-1 and PD-L1 in thymic epithelial neoplasms","volume":"30","author":"Weissferdt","year":"2017","journal-title":"Mod Pathol"},{"issue":"Suppl","key":"10.1016\/j.athoracsur.2018.08.037_bib15","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1097\/JTO.0b013e31821e7b12","article-title":"A\u00a0review of prognostic factors in thymic malignancies","volume":"6","author":"Detterbeck","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.athoracsur.2018.08.037_bib16","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/JTO.0000000000000215","article-title":"Prognostic factors for cure, recurrence and long-term survival after surgical resection of thymoma","volume":"9","author":"Safieddine","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.athoracsur.2018.08.037_bib17","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.athoracsur.2015.10.044","article-title":"Clinicopathologic and prognostic implications of programmed death ligand 1 expression in thymoma","volume":"101","author":"Yokoyama","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.athoracsur.2018.08.037_bib18","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1093\/ejcts\/ezs527","article-title":"The utility of [18f]-fluorodeoxyglucose positron emission tomography-computed tomography in thymic epithelial tumours","volume":"42","author":"Fukumoto","year":"2012","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.athoracsur.2018.08.037_bib19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2018.03.001","article-title":"Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma","volume":"119","author":"Kasahara","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.athoracsur.2018.08.037_bib20","doi-asserted-by":"crossref","first-page":"51630","DOI":"10.18632\/oncotarget.18257","article-title":"Prognostic significance of PD-L1 expression and 18F-FDG PET\/CT in surgical pulmonary squamous cell carcinoma","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.athoracsur.2018.08.037_bib21","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.athoracsur.2018.08.037_bib22","series-title":"WHO classification of tumors of the lung, pleura, thymus and heart","first-page":"187","author":"Travis","year":"2015"}],"container-title":["The Annals of Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003497518314383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003497518314383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T03:56:03Z","timestamp":1757735763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003497518314383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0003497518314383"],"URL":"https:\/\/doi.org\/10.1016\/j.athoracsur.2018.08.037","relation":{},"ISSN":["0003-4975"],"issn-type":[{"type":"print","value":"0003-4975"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathologic Features of Thymoma With the Expression of Programmed Death\u00a0Ligand 1","name":"articletitle","label":"Article Title"},{"value":"The Annals of Thoracic Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athoracsur.2018.08.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The Society of Thoracic Surgeons Published by Elsevier","name":"copyright","label":"Copyright"}]}}